Designation

China's CDE proposes breakthrough status for Lepu's CDH17 ADC MRG007 in colorectal cancer

The proposed designation covers advanced colorectal cancer that has progressed on two or more prior lines of systemic therapy. MRG007 is in a Phase Ib/II combination trial in China and won FDA orphan status in pancreatic cancer last month. ArriVent BioPharma holds rights outside Greater China under a January 2025 license valued at up to $1.207 billion.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Schematic animation of cadherin-17 proteins on the surface of gut-lining cells and tumour cells, and a Y-shaped antibody-drug conjugate with a small payload attached to its stem binding cadherin-17 on a tumour cell from outside.
MRG007: an antibody-drug conjugate aimed at CDH17. Watch the mechanism animation on the MRG007 page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call